SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:https://investor.resmed.com•Date:Thursday, ...

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The ...

Core Viewpoint - Resmed plans to release its financial and operational results for Q1 of fiscal year 2026 on October 30, 2025, after market close, followed by a management webcast to discuss the results and other relevant information [1]. Group 1: Earnings Release Details - The earnings release will occur on October 30, 2025, after the New York Stock Exchange closes [1]. - A webcast will be hosted by Resmed management to discuss the results and other forward-looking information [1]. - A replay of the earnings webcast will be available on Resmed's investor relations website approximately two hours after the live event [2]. Group 2: Company Overview - Resmed is dedicated to creating innovative health technologies aimed at improving the quality of life for individuals in 140 countries [2]. - The company focuses on AI-powered digital health solutions, cloud-connected devices, and intelligent software to enhance home healthcare [2]. - Resmed envisions a future where individuals can achieve better sleep and breathing through personalized care delivered at home [2].

Core Viewpoint - Resmed will present at the Bank of America Global Healthcare Conference 2025, highlighting its commitment to innovative health technologies and solutions [1]. Company Information - Resmed (NYSE: RMD, ASX: RMD) focuses on creating life-changing health technologies aimed at improving the quality of life for individuals [3]. - The company is dedicated to pioneering innovative technology that empowers millions across 140 countries to lead healthier lives [3]. - Resmed's offerings include AI-powered digital health solutions, cloud-connected devices, and intelligent software designed to enhance home healthcare [3]. - The company's vision is to enable every individual to reach their full potential through improved sleep and breathing, with care provided in their own homes [3]. Event Details - Mick Farrell, the chairman and CEO, along with Dr. Carlos Nunez, the chief medical officer, will present at the conference on September 23, 2025, at approximately 1:20 p.m. British Summer Time in London [1]. - Additional information about the event, including access to a live audio-only webcast, can be found on Resmed's investor relations website [2]. - A replay of the audio-only webcast will be available approximately 24 hours after the live event and will remain accessible for 30 days [2].

Core Insights - Resmed has elected Nicole Mowad-Nassar to its board of directors, effective August 15, 2025, while thanking Rich Sulpizio for his two decades of service as he retires from the board [1][5]. Group 1: Board Changes - Nicole Mowad-Nassar is currently the President of Specialty and U.S. Therapeutics Operations at AbbVie, managing a $6 billion commercial portfolio across 17 therapeutic areas and overseeing a workforce of 6,000 [2]. - Rich Sulpizio has served on Resmed's board since 2005, chairing the Compensation Committee and serving on the Audit Committee and Nominating and Governance Committee [5][6]. - Mowad-Nassar will serve as an independent director and has been appointed to the Compensation and Leadership Development Committee, standing for reelection at the 2025 Annual Meeting of Stockholders [4]. Group 2: Professional Background - Mowad-Nassar has over 30 years of experience in strategic, commercial, and operational roles within the pharmaceutical and healthcare sectors, with a focus on digital innovation [7]. - At AbbVie, she played a key role in the commercial integration of the $63 billion Allergan acquisition, ensuring continuity in product launches while minimizing operational disruption [3]. Group 3: Leadership Perspectives - Mick Farrell, Resmed's Chairman and CEO, highlighted Mowad-Nassar's extensive experience and commitment to patient access and digital engagement, indicating her potential to enhance the board's strategic direction [4]. - Farrell expressed gratitude for Sulpizio's contributions, noting his energy and people-first mindset during board discussions [6].

Company Overview - Resmed is set to release its financial and operational results for the fourth quarter of fiscal year 2025 on July 31, 2025, after the NYSE closes [1] - The company is dedicated to creating innovative health technologies that enhance the quality of life for individuals in 140 countries [2] - Resmed's vision includes empowering people to achieve better sleep and breathing through personalized home healthcare solutions [2] Earnings Webcast Details - Following the earnings release, Resmed management will host a webcast to discuss the results and other forward-looking information [1] - The earnings webcast will be accessible via a specific link, with no outside phone lines used for access [1] - A replay of the webcast will be available on Resmed's investor relations website approximately two hours after the live event [2] Contact Information - For investor inquiries, Resmed provides a dedicated contact number and email [3] - Media inquiries can also be directed to a specific contact number and email [3] - Additional details regarding the webcast timing and international access are provided [3][4]

Core Insights - Resmed has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia, highlighting its commitment to promoting sleep health in sports [1][3][6] Company Overview - Resmed is a leading health technology company focused on sleep, breathing, and home care, aiming to empower individuals to live healthier lives through innovative technologies [1][13] - The company operates in 140 countries and emphasizes the importance of quality sleep as a critical component of overall health [13] Campaign Details - The 'Tackle Your Sleep' campaign will feature legendary rugby players and aims to raise awareness about sleep health issues affecting both players and fans [3][5] - The campaign will provide advice and tools to improve sleep quality, emphasizing its significance alongside exercise and diet [3][5] Health Implications - Poor sleep can negatively impact mental and physical health, relationships, and daily performance, particularly for athletes [4][5] - A study indicated that half of the rugby and cricket players surveyed were classified as poor sleepers, with many experiencing significant daytime fatigue [4][5] Tour Information - The British & Irish Lions Tour will take place over six weeks, featuring matches in six cities across Australia, with an estimated 40,000 fans participating [2][8] - The Lions will play a total of 10 matches, including three Test matches against the Wallabies [8]

Core Insights - Resmed has acquired VirtuOx, enhancing its capabilities in virtual care and expanding access to diagnostic services for sleep, respiratory, and cardiac conditions [1][2][5] Group 1: Acquisition Details - The acquisition reflects Resmed's commitment to improving care delivery by making it more accessible and patient-friendly [2][4] - VirtuOx's virtual testing platform offers fast, flexible, and affordable diagnostic options, particularly for underdiagnosed conditions like obstructive sleep apnea (OSA) [3][5] - VirtuOx will operate as a fully owned subsidiary of Resmed, maintaining its brand and leadership team post-acquisition [6] Group 2: Strategic Implications - The integration of VirtuOx's diagnostic capabilities is expected to streamline the diagnostic process and reduce patient drop-off rates [4][5] - The acquisition supports the growing demand for home-based care, driven by increased awareness and digital innovation [5] - Resmed aims to deepen relationships with healthcare providers, sleep labs, and home medical equipment providers through this acquisition [5][6]